SARS-CoV-2 antibody profile of naturally infected and vaccinated individuals detected using qualitative, semi-quantitative and multiplex immunoassays
Authors:
- 28 August 2022
- journal article
- research article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 104 (4) , 115803
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Bio-Rad Laboratories
- Siemens
This publication has 18 references indexed in Scilit:
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 2021
- Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control studyBMJ, 2021
- SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)The Lancet, 2021
- Reinfection Rates Among Patients Who Previously Tested Positive for Coronavirus Disease 2019: A Retrospective Cohort StudyClinical Infectious Diseases, 2021
- The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 PandemicFrontiers in Immunology, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineNew England Journal of Medicine, 2021
- Evaluation of High-Throughput SARS-CoV-2 Serological Assays in a Longitudinal Cohort of Patients with Mild COVID-19: Clinical Sensitivity, Specificity, and Association with Virus Neutralization TestClinical Chemistry, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcomeScience Immunology, 2020
- Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisationJournal of Clinical Virology, 2020